Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Final Analysis of Phase 2a Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome (MDS), or Myelofibrosis (MF)

Blood (2024) 144 (Supplement 1): 1043.

https://doi.org/10.1182/blood-2024-206169

Published: 2024

Journal Articles

Sinusoidal Obstruction Syndrome in Adult Patients with B-Cell Acute Lymphoblastic Leukemia Treated with Inotuzumab Prior to Hematopoietic Stem Cell Transplantation

Blood (2022) 140 (Supplement 1): 10449–10450.

https://doi.org/10.1182/blood-2022-165839

Published: 2022

Journal Articles

Interim Results of a Phase 1/2 Study of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed/Refractory (r/r) ALL

Blood (2022) 140 (Supplement 1): 8985–8986.

https://doi.org/10.1182/blood-2022-170279

Published: 2022

Journal Articles

Long Term Outcomes of Patients with Chronic Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation in the Era of Oral Tyrosine Kinase Inhibitors

Blood (2022) 140 (Supplement 1): 12945–12946.

https://doi.org/10.1182/blood-2022-170009

Published: 2022

Journal Articles

Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions

Blood (2022) 140 (Supplement 1): 6020–6022.

https://doi.org/10.1182/blood-2022-158288

Published: 2022

Journal Articles

Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Blood (2022) 140 (Supplement 1): 10568–10570.

https://doi.org/10.1182/blood-2022-163652

Published: 2022

Journal Articles

Renal Impairment Adversely Impacts Melphalan-Induced Severe GvHD- and GI Toxicity- Free Survival (MGTFS) in Patients Undergoing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation

Blood (2022) 140 (Supplement 1): 7595–7596.

https://doi.org/10.1182/blood-2022-170655

Published: 2022

Journal Articles

Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Blood (2022) 140 (Supplement 1): 4821–4822.

https://doi.org/10.1182/blood-2022-164639

Published: 2022

Journal Articles

Myeloablative Vs Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation in Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

Blood (2022) 140 (Supplement 1): 12819–12820.

https://doi.org/10.1182/blood-2022-164657

Published: 2022

Journal Articles

Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis

Blood (2022) 140 (Supplement 1): 1872–1874.

https://doi.org/10.1182/blood-2022-170323

Published: 2022

Journal Articles

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Adults with Ph-like ALL

Blood (2021) 138 (Supplement 1): 3955.

https://doi.org/10.1182/blood-2021-153125

Published: 2021

Journal Articles

The Impact of Letermovir (LTV) Prophylaxis on Early Cytomegalovirus Infection (CMVi) and Outcomes in the Adult Allogeneic Hematopoietic Cell Transplantation (alloHCT) Recipients with High-Risk Donor Type

Sanjeet S Dadwal, Dongyun Yang, Guido Marcucci, Sally Mokhtari, Bernard Tegtmeier, Joycelynne Palmer, Eileen P. Smith, Randy Taplitz, Andrew S. Artz, Peter T. Curtin, Ricardo Spielberger, Amandeep Salhotra, Anthony S. Stein, Stephen J Forman, Monzr M. Al Malki, Ryotaro Nakamura

Blood (2021) 138 (Supplement 1): 1776.

https://doi.org/10.1182/blood-2021-153784

Published: 2021

Journal Articles

A Phase II Study of Pegylated Asparaginase, Cyclophosphamide, Rituximab, and Dasatinib Added to the UCSF 8707 (Linker 4-drug) Regimen with Liposomal Cytarabine CNS Prophylaxis for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401

Matthew J. Wieduwilt, MD PhD, Brian A. Jonas, MD, Gary J. Schiller, MD, Lin Liu, PhD, Carolyn Mulroney, MD, Gabriel N. Mannis, MD, Dimitrios Tzachanis, MD PhD, Januario E. Castro, MD, Edward D Ball, MD, Peter T. Curtin, MD, Charalambos Andreadis, MD, Aaron C. Logan, MD PhD, Jesika Reiner, MPH, Lloyd E. Damon, MD

Blood (2018) 132 (Supplement 1): 4018.

https://doi.org/10.1182/blood-2018-99-117469

Published: 2018

Journal Articles

A Phase 1 Trial of Ibrutinib (IBR) and Azacitidine (AZA) for the Treatment of Higher-Risk Myelodysplastic Syndromes (HR-MDS): Updated Results of University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

Brian A. Jonas, MD PhD, Peter T. Curtin, MD, Gary J. Schiller, MD, Deepa Jeyakumar, MD, Matthew J. Wieduwilt, MD PhD, Mehrdad Abedi, MD, Rafael Bejar, MD PhD, Helen Chow, MD, Leslie G. Oesterich, MD, Aaron C. Logan, MD PhD

Blood (2018) 132 (Supplement 1): 3088.

https://doi.org/10.1182/blood-2018-99-119237

Published: 2018

Journal Articles

A Phase 1 Trial of the Combination of Ibrutinib and Azacitidine for the Treatment of Higher Risk Myelodysplastic Syndromes: University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

Brian A Jonas, MD PhD, Aaron C. Logan, MDPhDMPhil, Deepa Jeyakumar, MD, Mehrdad Abedi, MD, Rafael Bejar, MD PhD, Matthew J. Wieduwilt, Leslie G. Oesterich, MD, Peter T. Curtin, MD

Blood (2017) 130 (Supplement 1): 2973.

https://doi.org/10.1182/blood.V130.Suppl_1.2973.2973

Published: 2017

Journal Articles

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q

Azra Raza, James A. Reeves, Eric J. Feldman, Gordon W. Dewald, John M. Bennett, H. Joachim Deeg, Luke Dreisbach, Charles A. Schiffer, Richard M. Stone, Peter L. Greenberg, Peter T. Curtin, Virginia M. Klimek, Jamile M. Shammo, Deborah Thomas, Robert D. Knight, Michele Schmidt, Kenton Wride, Jerome B. Zeldis, Alan F. List

Blood (2008) 111 (1): 86–93.

https://doi.org/10.1182/blood-2007-01-068833

Published: 2008

Includes: Supplemental data

Journal Articles

Applying the Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) in Myeloablative MUD Transplants Predicts NRM and OS Using a Modified 2-Tier Scoring System.

Tibor Kovacsovics, Byung Park, Brandon Hayes-Lattin, Jose F. Leis, Peter T. Curtin, Gabrielle Meyers, Elliot Epner, Richard T. Maziarz

Blood (2007) 110 (11): 1988.

https://doi.org/10.1182/blood.V110.11.1988.1988

Published: 2007

Journal Articles

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics

Daniel J. DeAngelo, Richard M. Stone, Mark L. Heaney, Stephen D. Nimer, Ronald L. Paquette, Rebecca B. Klisovic, Michael A. Caligiuri, Michael R. Cooper, Jean-Michel Lecerf, Michael D. Karol, Shihong Sheng, Nick Holford, Peter T. Curtin, Brian J. Druker, Michael C. Heinrich

Blood (2006) 108 (12): 3674–3681.

https://doi.org/10.1182/blood-2006-02-005702

Published: 2006

Journal Articles

Prognostic Models for Predicting Outcomes after Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory Hodgkin’s Disease: How Predictive Are They?.

Jose F. Leis, MD, PhD, Keith S. Hansen, MD, Peter T. Curtin, MD, Brandon M. Hayes-Lattin, MD, Keith S. Lanier, MD, Nathan R. Stanton, Charles D. Callaway, Ceder J. Fowler, Adam M. Dunn, Daniel Gruenberg, MD, Michael J. Mauro, MD, Gerald M. Segal, MD, Lisa K. Hansen, Jeffrey I. Menashe, MD, Tibor J. Kovacsovics, MD, Aleksandra Simic, MD, Richard T. Maziarz, MD.

Blood (2005) 106 (11): 5509.

https://doi.org/10.1182/blood.V106.11.5509.5509

Published: 2005

Journal Articles

Safety and Tolerability of Anti-Bacterial Prophylaxis during the Post-Engraftment Phase after Myeloablative Hematopoietic Stem Cell Transplantation.

Brandon Hayes-Lattin, MD, Joseph Bubalo, PharmD, Adam Dunn, Nan Subbiah, Bryon Allen, Suzanne Balleisen, Peter T. Curtin, MD, Carol Jacoby, Jose F. Leis, MD, PhD, Michael J. Mauro, MD, Aleksandra Simic, MD, Susan Schubach, Richard T. Maziarz, MD

Blood (2004) 104 (11): 5093.

https://doi.org/10.1182/blood.V104.11.5093.5093

Published: 2004

NARROW

Final Analysis of Phase 2a Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome (MDS), or Myelofibrosis (MF)

Sinusoidal Obstruction Syndrome in Adult Patients with B-Cell Acute Lymphoblastic Leukemia Treated with Inotuzumab Prior to Hematopoietic Stem Cell Transplantation

Interim Results of a Phase 1/2 Study of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed/Refractory (r/r) ALL

Long Term Outcomes of Patients with Chronic Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation in the Era of Oral Tyrosine Kinase Inhibitors

Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions

Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Renal Impairment Adversely Impacts Melphalan-Induced Severe GvHD- and GI Toxicity- Free Survival (MGTFS) in Patients Undergoing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation

Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Myeloablative Vs Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation in Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Adults with Ph-like ALL

The Impact of Letermovir (LTV) Prophylaxis on Early Cytomegalovirus Infection (CMVi) and Outcomes in the Adult Allogeneic Hematopoietic Cell Transplantation (alloHCT) Recipients with High-Risk Donor Type

A Phase 1 Trial of Ibrutinib (IBR) and Azacitidine (AZA) for the Treatment of Higher-Risk Myelodysplastic Syndromes (HR-MDS): Updated Results of University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

A Phase 1 Trial of the Combination of Ibrutinib and Azacitidine for the Treatment of Higher Risk Myelodysplastic Syndromes: University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q

Applying the Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) in Myeloablative MUD Transplants Predicts NRM and OS Using a Modified 2-Tier Scoring System.

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics

Prognostic Models for Predicting Outcomes after Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory Hodgkin’s Disease: How Predictive Are They?.

Safety and Tolerability of Anti-Bacterial Prophylaxis during the Post-Engraftment Phase after Myeloablative Hematopoietic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only